Vickers A, Leng X. The impact of life expectancy exclusion criteria on survival curve extrapolation. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S406. doi: 10.1016/j.jval.2023.09.2131
Vickers A. The performance of anchored and unanchored population adjustment methods (matching-adjusted indirect comparison, simulated treatment comparison, and multiple imputation marginalization) in castration resistant prostate cancer. Poster presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S400-1. doi: 10.1016/j.jval.2023.09.2098
Jen MH, Kiiskinen U, Khanal M, Han Y, Hess L, Tian W, Vickers A. Matching Adjusted Indirect Comparison (MAIC) of selpercatinib Vs cabozantinib in RET mutation-positive advanced Medullary Thyroid Cancer (MTC). Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S18. doi: 10.1016/j.jval.2023.09.094
Vickers A. A comparison of the performance of a range of trial-level surrogacy methods. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S357. doi: 10.1016/j.jval.2022.09.1771
Jen MH, Sonksen M, Kiiskinen U, Wolowacz S, Vickers AD, Hawe E. Surrogate outcomes for overall survival in pretreated non-small cell lung cancer: expanding the prediction range. Poster presented at the Virtual ISPOR Europe 2021; December 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
Ainsworth CM, Vickers AD, Le Moine J. Assessing the robustness of network meta-analysis of atypical antipsychotics in the presence of heterogeneity. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct; 20(9):A767. doi: 10.1016/j.jval.2017.08.2189
Zuluaga S, Hess LM, Wolowacz S, Dyachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for the treatment of locally advanced or metastatic soft tissue sarcoma in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A108.
Bertwistle D, D'yachkova Y, Vickers AD, Hawe E, Fernandez M, Drove N, Lorenzo M, Wolowacz S. Comparative efficacy and saftey of interventions in the treatment of advanced soft tissue sarcoma: a systematic review and network meta analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A712.
Vickers AD. Survival network meta-analysis: hazard ratios versus reconstructed survival data. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A90.